Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 4-hydroxy-n-demethyltamoxifen
2. 4-hydroxy-n-desmethyltamoxifen
3. 4-hydroxy-n-desmethyltamoxifen, (z)-isomer
4. Z-endoxifen
1. 112093-28-4
2. Z-endoxifen
3. 4-hydroxy-n-desmethyltamoxifen
4. Endoxifen Z-isomer
5. N-desmethyl-4-hydroxytamoxifen
6. (z)-endoxifen
7. 110025-28-0
8. (z)-4-hydroxy-n-desmethyl Tamoxifen (mixture Of Isomers)
9. 4ohndtam
10. Nsc-749798
11. N-desmethyl-4-hydroxy Tamoxifen (approx. 1:1 E/z Mixture)
12. 4-hydroxy-n-desmethyl-tamoxifen
13. Chebi:80555
14. 46af8680rc
15. 4-[(z)-1-[4-[2-(methylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol
16. (z)-4-hydroxy-n-desmethyl Tamoxifen (contains Up To 10% E Isomer)
17. Unii-46af8680rc
18. 4-hydroxy-n-desmethyltamoxifen, (z)-isomer
19. 4-hydroxy-n-desmethyl Tamoxifen
20. (z)-4-(1-(4-(2-(methylamino)ethoxy)phenyl)-2-phenylbut-1-en-1-yl)phenol
21. Endoxifenz-isomer
22. Phenol, 4-((1z)-1-(4-(2-(methylamino)ethoxy)phenyl)-2-phenyl-1-buten-1-yl)-
23. Endoxifen(e/z=1:1)
24. Endoxifen [who-dd]
25. Chembl1093458
26. Schembl10107920
27. Gtpl10203
28. Dtxsid80149880
29. Ex-a645
30. Phenol, 4-[(1z)-1-[4-[2-(methylamino)ethoxy]phenyl]-2-phenyl-1-buten-1-yl]-
31. Bcp15866
32. Ex-a1970
33. 4-[1-[4-[2-(methylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol
34. Bdbm50435003
35. Hy-18719e
36. Nsc746494
37. Nsc749798
38. Nsc777380
39. Zinc22056306
40. Nsc 749798
41. Nsc-746494
42. Nsc-777380
43. Ncgc00386714-01
44. Ac-36810
45. Be172975
46. Bs-42369
47. B7481
48. Cs-0028594
49. (z)-4-hydroxy-n-desmethyl Tamoxifen (endoxifen)
50. A894656
51. N-desmethyl-4-hydroxytamoxifen, Mixture Of Isomers
52. 4-hydroxy-n-desmethyl Tamoxifen ((e/z)-endoxifen)
53. J-002363
54. W-200834
55. Q27149598
56. N-desmethyl-4-hydroxy Tamoxifen(approx. 1:1 E/z Mixture)
57. (z)-4-hydroxy-n-desmethyl Tamoxifen(contains Up To 10% E Isomer)
58. (e/z)-4-(1-(4-(2-(methylamino)ethoxy)phenyl)-2-phenylbut-1-enyl)phenol
59. (z)-4-(1-(4-(2-(methylamino)ethoxy)phenyl)-2-phenylbut-1-enyl)phenol
60. 4-[(~{z})-1-[4-[2-(methylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol
61. N-desmethyl-4-hydroxytamoxifen, Mixture Of Isomers, Analytical Standard
62. (e/z)-4-[1-[4-[2-(methylamino)ethoxy]phenyl]-2-phenyl-1-buten-1-yl]-phenol
63. 4-[(1z)-1-{4-[2-(methylamino)ethoxy]phenyl}-2-phenylbut-1-en-1-yl]phenol
64. N-methyl-2-[4-[(e)-1-(4-hydroxyphenyl)-2-phenyl-1-butenyl]phenoxy]ethanamine
65. Phenol, 4-(1-(4-(2-(methylamino)ethoxy]phenyl)-2-phenyl-1-butenyl)-, (z)-
| Molecular Weight | 373.5 g/mol |
|---|---|
| Molecular Formula | C25H27NO2 |
| XLogP3 | 6.3 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 8 |
| Exact Mass | 373.204179104 g/mol |
| Monoisotopic Mass | 373.204179104 g/mol |
| Topological Polar Surface Area | 41.5 Ų |
| Heavy Atom Count | 28 |
| Formal Charge | 0 |
| Complexity | 467 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Endoxifen has known human metabolites that include Endoxifen O-glucuronide and Endoxifen O-sulfate.
Endoxifen is a known human metabolite of 4-Hydroxytamoxifen and N-Desmethyltamoxifen.
S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560
Drugs in Development
Details:
Endoxifen (z-endoxifen) is the most active metabolite of the FDA approved selective estrogen receptor modulator (SERM), tamoxifen. It has demonstrated that the anti-estrogenic effects and is being evaluated for ER+/HER2+ breast cancer.
Lead Product(s): Endoxifen
Therapeutic Area: Oncology Brand Name: Endoxifen
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Quantum Leap Healthcare
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2023
Lead Product(s) : Endoxifen
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Quantum Leap Healthcare
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Endoxifen (z-endoxifen) is the most active metabolite of the FDA approved selective estrogen receptor modulator (SERM), tamoxifen. It has demonstrated that the anti-estrogenic effects and is being evaluated for ER+/HER2+ breast cancer.
Brand Name : Endoxifen
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 28, 2023
Details:
Endoxifen (z-endoxifen) is the most active metabolite of the FDA approved selective estrogen receptor modulator (SERM), tamoxifen. It has demonstrated that the anti-estrogenic effects and is being evaluated for ER+/HER2+ breast cancer.
Lead Product(s): Endoxifen
Therapeutic Area: Oncology Brand Name: Endoxifen
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2023
Details : Endoxifen (z-endoxifen) is the most active metabolite of the FDA approved selective estrogen receptor modulator (SERM), tamoxifen. It has demonstrated that the anti-estrogenic effects and is being evaluated for ER+/HER2+ breast cancer.
Brand Name : Endoxifen
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 12, 2023
Details:
Under the agreement, Societal CDMO will provide a range of its Clinical Trial Services offerings focused on Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, the most active metabolite of the FDA approved SERM, tamoxifen.
Lead Product(s): Endoxifen
Therapeutic Area: Oncology Brand Name: Endoxifen
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Atossa Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 23, 2023
Lead Product(s) : Endoxifen
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Atossa Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, Societal CDMO will provide a range of its Clinical Trial Services offerings focused on Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, the most active metabolite of the FDA approved SERM, tamoxifen...
Brand Name : Endoxifen
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 23, 2023
Details:
(Z)-endoxifen is the most active metabolite of the FDA approved selective estrogen receptor modulator (SERM), tamoxifen. It has demonstrated that the anti-estrogenic effects and is being evaluated for ER+/HER2+ breast cancer.
Lead Product(s): Endoxifen
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Quantum Leap Healthcare
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2023
Lead Product(s) : Endoxifen
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Quantum Leap Healthcare
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : (Z)-endoxifen is the most active metabolite of the FDA approved selective estrogen receptor modulator (SERM), tamoxifen. It has demonstrated that the anti-estrogenic effects and is being evaluated for ER+/HER2+ breast cancer.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 21, 2023
Details:
Endoxifen, an active metabolite of tamoxifen, which is an FDA-approved drug to treat ovarian and breast cancer. Endoxifen administered to breast cancer patients prior to surgery.
Lead Product(s): Endoxifen
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2021
Atossa Therapeutics Shares Jump 35% Ahead of Data on Endoxifen in Breast Cancer Surgery Patients
Details : Endoxifen, an active metabolite of tamoxifen, which is an FDA-approved drug to treat ovarian and breast cancer. Endoxifen administered to breast cancer patients prior to surgery.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 07, 2021
Details:
The study results show that treatment with Atossa’s proprietary Endoxifen for 20 days prior to unilateral mastectomy and for 18 months after surgery as an adjuvant did not lead to vasomotor symptoms commonly associated with tamoxifen.
Lead Product(s): Endoxifen
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 30, 2020
Atossa Therapeutics Announces Findings from FDA-Approved Expanded Access Treatment with Endoxifen
Details : The study results show that treatment with Atossa’s proprietary Endoxifen for 20 days prior to unilateral mastectomy and for 18 months after surgery as an adjuvant did not lead to vasomotor symptoms commonly associated with tamoxifen.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 30, 2020
Details:
Completed treating a sufficient number of patients to permit an initial report of study results from the pilot portion of the study.
Lead Product(s): Endoxifen
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 02, 2020
Atossa Therapeutics Announces Clinical Progress
Details : Completed treating a sufficient number of patients to permit an initial report of study results from the pilot portion of the study.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 02, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
